Trial Information
A Randomized, Open-Label, Dose-Timing Study of Darbepoetin Alfa Administered Once Every 3 Weeks (Q3W) by Subcutaneous (SC) Injection for Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy
Inclusion Criteria
- Patients with non-myeloid malignancies * Patients receiving at least 12 weeks of
chemotherapy on a 3-week cycle schedule * Patients with anemia (hgb >/= 9.0 and =
11.0 g/dL)
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Principal Investigator
MD
Investigator Role:
Study Director
Investigator Affiliation:
Amgen
Authority:
United States: Food and Drug Administration
Study ID:
20010162
NCT ID:
NCT00036023
Start Date:
Completion Date:
Related Keywords:
- Lymphoma
- Breast Neoplasms
- Lung Neoplasms
- Multiple Myeloma
- Chronic Lymphocytic Leukemia
- Breast Neoplasms
- Neoplasms
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Lung Neoplasms
- Lymphoma
- Multiple Myeloma
- Neoplasms, Plasma Cell